Profile data is unavailable for this security.
About the company
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
- Revenue in USD (TTM)48.19bn
- Net income in USD7.05bn
- Incorporated1933
- Employees32.50k
- LocationBristol-Myers Squibb CoRoute 206 And Province Line RoadPRINCETON 08543United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://www.bms.com
Mergers & acquisitions
| Acquired company | BMY:NYQ since announced | Transaction value |
|---|---|---|
| Orbital Therapeutics Inc | 35.94% | 1.50bn |
| 2Seventy Bio Inc | -0.57% | 238.66m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc | 14.34bn | 4.55bn | 84.91bn | 15.41k | 19.14 | 2.72 | 16.67 | 5.92 | 41.96 | 41.55 | 131.98 | 295.71 | 0.3663 | 0.6934 | 2.40 | 930,752.80 | 11.62 | 16.41 | 13.00 | 18.57 | 86.56 | 87.14 | 31.72 | 36.23 | 3.56 | -- | 0.0797 | 1.50 | 0.9921 | 11.04 | 3.10 | 5.31 | 14.58 | -- |
| Bristol-Myers Squibb Co | 48.19bn | 7.05bn | 123.70bn | 32.50k | 17.56 | 6.62 | 11.18 | 2.57 | 3.46 | 3.46 | 23.64 | 9.18 | 0.5278 | 5.03 | 5.02 | 1,482,892.00 | 7.73 | 3.92 | 10.43 | 5.05 | 72.63 | 76.32 | 14.64 | 8.34 | 1.14 | 16.84 | 0.7091 | 122.54 | -0.2195 | 2.54 | 178.83 | -- | 11.73 | 0.658 |
| Vertex Pharmaceuticals Inc | 12.00bn | 3.95bn | 124.83bn | 6.10k | 32.05 | 6.69 | 42.81 | 10.40 | 15.33 | 15.33 | 46.51 | 73.49 | 0.4982 | 1.14 | 6.55 | -- | 16.41 | 13.29 | 19.40 | 15.74 | 86.24 | 86.99 | 32.94 | 25.71 | 2.46 | -- | -- | -- | 8.90 | 14.10 | 838.09 | 7.83 | -- | -- |
| Pfizer Inc | 62.58bn | 7.75bn | 156.81bn | 81.00k | 20.35 | -- | 11.26 | 2.51 | 1.36 | 1.36 | 10.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 75.81 | 69.03 | 12.44 | 19.52 | -- | 9.38 | -- | -- | -1.65 | 8.48 | -3.42 | 3.16 | -- | 2.50 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 177.85m | 8.74% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 104.30m | 5.12% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 97.98m | 4.81% |
| Charles Schwab Investment Management, Inc.as of 31 Dec 2025 | 71.32m | 3.50% |
| JPMorgan Investment Management, Inc.as of 31 Dec 2025 | 53.23m | 2.62% |
| Geode Capital Management LLCas of 31 Dec 2025 | 52.64m | 2.59% |
| Norges Bank Investment Managementas of 31 Dec 2025 | 36.10m | 1.77% |
| Columbia Management Investment Advisers LLCas of 30 Sep 2025 | 29.78m | 1.46% |
| BlackRock Investment Management (UK) Ltd.as of 31 Dec 2025 | 24.99m | 1.23% |
| PRIMECAP Management Co.as of 31 Dec 2025 | 24.88m | 1.22% |
